Evelo Biosciences, Inc. (EVLO) financial statements (2020 and earlier)
Company profile
| Business Address |
620 MEMORIAL DRIVE CAMBRIDGE, MA 02139 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments, including: | 97 | 148 | ||
| Cash and cash equivalents | 97 | 93 | ||
| Short-term investments | 55 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 0 | (0) | ||
| Other undisclosed current assets | 4 | 4 | ||
| Total current assets: | 101 | 152 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 8 | 7 | ||
| Other noncurrent assets | 2 | 1 | ||
| Total noncurrent assets: | 10 | 8 | ||
| TOTAL ASSETS: | 111 | 160 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 9 | 6 | ||
| Accounts payable | 1 | 2 | ||
| Accrued liabilities | 8 | 5 | ||
| Other liabilities | 0 | 3 | ||
| Total current liabilities: | 10 | 9 | ||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 20 | 12 | ||
| Long-term debt, excluding current maturities | 20 | 12 | ||
| Liabilities, other than long-term debt | 1 | 1 | ||
| Deferred rent credit | 1 | 1 | ||
| Other liabilities | 0 | 0 | ||
| Total noncurrent liabilities: | 21 | 14 | ||
| Total liabilities: | 31 | 23 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 81 | 137 | ||
| Common stock | 0 | 0 | ||
| Additional paid in capital | 257 | 250 | ||
| Accumulated other comprehensive loss | (0) | |||
| Accumulated deficit | (176) | (113) | ||
| Total stockholders' equity: | 81 | 137 | ||
| TOTAL LIABILITIES AND EQUITY: | 111 | 160 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | ||
|---|---|---|---|
| Operating expenses | (80) | (58) | |
| Operating loss: | (80) | (58) | |
| Nonoperating income | 1 | 1 | |
| Investment income, nonoperating | 2 | 2 | |
| Other nonoperating expense | (0) | (0) | |
| Interest and debt expense | (1) | (1) | |
| Loss before gain (loss) on sale of properties: | (79) | (58) | |
| Other undisclosed net loss | (0) | ||
| Net loss: | (79) | (58) | |
| Other undisclosed net income attributable to parent | 1 | 1 | |
| Net loss attributable to parent: | (78) | (57) | |
| Preferred stock dividends and other adjustments | (4) | ||
| Net loss available to common stockholders, diluted: | (78) | (61) | |
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | ||
|---|---|---|---|
| Net loss: | (79) | (58) | |
| Comprehensive loss: | (79) | (58) | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 1 | 1 | |
| Comprehensive loss, net of tax, attributable to parent: | (78) | (57) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.